Adoption of injectable naltrexone in U.S. Substance use disorder treatment programs

Journal of Studies on Alcohol and Drugs

Volumn 76, Issue 1, 2015, Pages 143-151

  Aletraris, Lydia ^a   Edmond, Mary Bond ^a   Roman, Paul M ^a  

^a UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NALTREXONE;

ALCOHOL-RELATED DISORDERS; DRUG DEPENDENCE TREATMENT; HUMAN; OPIOID-RELATED DISORDERS; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ALCOHOL-RELATED DISORDERS; HUMANS; NALTREXONE; OPIOID-RELATED DISORDERS; SUBSTANCE ABUSE TREATMENT CENTERS; UNITED STATES;

EID: 84923167521     PISSN: 19371888     EISSN: 19384114     Source Type: Journal    
DOI: 10.15288/jsad.2015.76.143     Document Type: Article

References (56)

1. Abraham, A. J., Knudsen, H. K., & Roman, P. M. (2011). A longitudinal examination of alcohol pharmacotherapy adoption in substance use disorder treatment programs: Patterns of sustainability and discontinuation. Journal of Studies on Alcohol and Drugs, 72, 669-677.
2. Abraham, A. J., & Roman, P. M. (2010). Early adoption of injectable naltrexone for alcohol-use disorders: Findings in the private-treatment sector. Journal of Studies on Alcohol and Drugs, 71, 460-466.
3. Alcoholics Anonymous. (1984). The AA member, medication, and other drugs. New York, NY: Author.
4. Allison, P. D. (2009). “Missing data.” In R. E. Millsap & A. Maydeu-Olivares (Eds.), The SAGE handbook of quantitative methods in psychology (pp. 73-91). London, England: Sage Publications Ltd.
5. American Society of Addiction Medicine. (2013). Advancing access to addiction medications: Implications for opioid addiction treatment. Retrieved from http://www.asam.org/docs/advocacy/Implications-for-Opioid-Addiction-Treatment.
6. Baser, O., Chalk, M., Fiellin, D. A., & Gastfriend, D. R. (2011). Cost and utilization outcomes of opioid-dependence treatments. American Journal of Managed Care, 17, Suppl 8, S235-S248.
7. Bouza, C., Angeles, M., Muñoz, A., & Amate, J. M. (2004). Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: A systematic review. Addiction, 99, 811-828.
8. Center for Substance Abuse Treatment. (2009). Incorporating alcohol pharmacotherapies into medical practice. Treatment Improvement Protocol (TIP) Series, No. 49, (SMA) 09-4380. Rockville, MD: Substance Abuse and Mental Health Services Administration.
9. Chriqui, J. F., Terry-McElrath, Y., McBride, D. C., Eidson, S. S., & Vander-Waal, C. J. (2007). Does state certification or licensure influence outpatient substance abuse treatment program practices? Journal of Behavioral Health Services & Research, 34, 309-328.
10. Davern, M., McAlpine, D., Beebe, T. J., Ziegenfuss, J., Rockwood, T., & Call, K. T. (2010). Are lower response rates hazardous to your health survey? An analysis of three state telephone health surveys. Health Services Research, 45, 1324-1344.
11. Ducharme, L. J., Knudsen, H. K., & Roman, P. M. (2006). Trends in the adoption of medications for alcohol dependence. Journal of Clinical Psychopharmacology, 26, Suppl 1, S13-S19.
12. Ducharme, L. J., Mello, H. L., Roman, P. M., Knudsen, H. K., & Johnson, J. A. (2007). Service delivery in substance abuse treatment: Reexamining “comprehensive” care. Journal of Behavioral Health Services & Research, 34, 121-136.
13. Friedmann, P. D., Hoskinson, R., Jr., Gordon, M., Schwartz, R., Kinlock, T., Knight, K., Frisman, L. K., & the MAT Working Group of CJ-DATS. (2012). Medication-assisted treatment in criminal justice agencies affiliated with the criminal justice-drug abuse treatment studies (CJ-DATS): Availability, barriers, and intentions. Substance Abuse, 33, 9-18.
14. Fuller, B. E., Rieckmann, T., McCarty, D., Smith, K. W., & Levine, H. (2005). Adoption of naltrexone to treat alcohol dependence. Journal of Substance Abuse Treatment, 28, 273-280.
15. Garbutt, J. C., Kranzler, H. R., O’Malley, S. S., Gastfriend, D. R., Pettinati, H. M., Silverman, B. L., Ehrich, E. W., & the Vivitrex Study Group. (2005). Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: A randomized controlled trial. Journal of the American Medical Association, 293, 1617-1625.
16. Gastfriend, D. R. (2011). Intramuscular extended-release naltrexone: Current evidence. Annals of the New York Academy of Sciences, 1216, 144-166.
17. Gastfriend, D. R., Dong, Q., Loewy, J., Silverman, B., & Ehrich, E. W. (2005). Effect of long-acting injectable naltrexone on durability of drinking outcomes [Abstract]. Alcoholism: Clinical and Experimental Research, 29, Supplement S1, 77A.
18. Gueorguieva, R., Wu, R., Krystal, J. H., Donovan, D., & O’Malley, S. S. (2013). Temporal patterns of adherence to medications and behavioral treatment and their relationship to patient characteristics and treatment response. Addictive Behaviors, 38, 2119-2127.
19. Hartung, D. M., McCarty, D., Fu, R., Wiest, K., Chalk, M., & Gastfriend, D. R. (2014). Extended-release naltrexone for alcohol and opioid dependence: A meta-analysis of healthcare utilization studies. Journal of Substance Abuse Treatment, 47, 113-121.
20. Heinrich, C. J., & Cummings, G. R. (2014). Adoption and diffusion of evidence-based addiction medications in substance abuse treatment. Health Services Research, 49, 127-152.
21. Heinrich, C. J., & Hill, C. J. (2008). Role of state policies in the adoption of naltrexone for substance abuse treatment. Health Services Research, 43, 951-970.
22. Howell, D. C. (2007). Statistical methods for psychology. Belmont, CA: Thomson Wadsworth.
23. Jonas, D. E., Amick, H. R., Feltner, C., Bobashev, G., Thomas, K., Wines, R., Garbutt, J. C. (2014). Pharmacotherapy for adults with alcohol use disorders in outpatient settings: A systematic review and meta- analysis. Journal of the American Medical Association, 311, 1889-1900.
24. Knudsen, H. K., & Roman, P. M. (2012). Financial factors and the implementation of medications for treating opioid use disorders. Journal of Addiction Medicine, 6, 280-286.
25. Knudsen, H. K., Roman, P. M., Ducharme, L. J., & Johnson, J. A. (2005). Organizational predictors of pharmacological innovation adoption: The case of disulfiram. Journal of Drug Issues, 35, 559-573.
26. Kranzler, H. R., Stephenson, J. J., Montejano, L., Wang, S., & Gastfriend, D. R. (2008). Persistence with oral naltrexone for alcohol treatment: Implications for health-care utilization. Addiction, 103, 1801-1808.
27. Kranzler, H. R., Wesson, D. R., & Billot, L., & the Drug Abuse Sciences Naltrexone Depot Study Group. (2004). Naltrexone depot for treatment of alcohol dependence: A multicenter, randomized, placebo-controlled clinical trial. Alcoholism: Clinical and Experimental Research, 28, 1051-1059.
28. Krupitsky, E. M., & Blokhina, E. A. (2010). Long-acting depot formulations of naltrexone for heroin dependence: A review. Current Opinion in Psychiatry, 23, 210-214.
29. Kubiak, S. P., Arfken, C. L., & Gibson, E. S. (2009). Departments of corrections as purchasers of community-based treatment: A national study. Journal of Substance Abuse Treatment, 36, 420-427.
30. Lee, J. D., Grossman, E., Huben, L., Manseau, M., McNeely, J., Rotrosen, J., Gourevitch, M. N. (2012). Extended-release naltrexone plus medical management alcohol treatment in primary care: Findings at 15 months. Journal of Substance Abuse Treatment, 43, 458-462.
31. Lichtenberg, F. R., & Philipson, T. J. (2002). The dual effects of intellectual property regulations: Within- and between-patent competition in the U.S. pharmaceuticals industry. Journal of Law & Economics, 45, 643-672.
32. Mark, T. L., Kranzler, H. R., Poole, V. H., Hagen, C. A., McLeod, C., & Crosse, S. (2003). Barriers to the use of medications to treat alcoholism. American Journal on Addictions, 12, 281-294.
33. Marlowe, D. B. (2011). Evidence-based policies and practices for drug- involved offenders. The Prison Journal, 91, Suppl, 27S-47S.
34. Matusow, H., Dickman, S. L., Rich, J. D., Fong, C., Dumont, D. M., Hardin, C., Rosenblum, A. (2013). Medication assisted treatment in US drug courts: Results from a nationwide survey of availability, barriers and attitudes. Journal of Substance Abuse Treatment, 44, 473-480.
35. McDonald, R. C. (2008). Managing the intersection of medical and pharmacy benefits. Journal of Managed Care Pharmacy, 14, Suppl, S7-S11.
36. McMillan, G. P., & Lapham, S. C. (2005). Staff perspectives on methadone maintenance therapy (MMT) in a large southwestern jail. Addiction Research and Theory, 13, 53-63.
37. Mealing, N. M., Banks, E., Jorm, L. R., Steel, D. G., Clements, M. S., & Rogers, K. D. (2010). Investigation of relative risk estimates from studies of the same population with contrasting response rates and designs. BMC Medical Research Methodology, 10, 26.
38. Mee-Lee, D. L., Gartner, L., Miller, M. M., Shulman, G. D., & Wilford, B. B. (1996). Patient placement criteria for the treatment of substance related disorders (2nd ed.). Chevy Chase, MD: American Society of Addiction Medicine.
39. National Institute on Drug Abuse. (2012). Principles of drug abuse treatment: A research-based guide (NIH Publication No. 02-4180). Rockville, MD: Author.
40. O’Malley, S. S., Garbutt, J. C., Gastfriend, D. R., Dong, Q., & Kranzler, H. R. (2007). Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment. Journal of Clinical Psychopharmacology, 27, 507-512.
41. Oser, C. B., & Roman, P. M. (2008). A categorical typology of naltrexoneadopting private substance abuse treatment centers. Journal of Substance Abuse Treatment, 34, 433-442.
42. Rich, J. D., Boutwell, A. E., Shield, D. C., Key, R. G., McKenzie, M., Clarke, J. G., & Friedmann, P. D. (2005). Attitudes and practices regarding the use of methadone in US state and federal prisons. Journal of Urban Health, 82, 411-419.
43. Rogers, E. M. (2003). Diffusion of innovations. New York, NY: Free Press.
44. Roman, P. M., & Johnson, J. A. (2002). Adoption and implementation of new technologies in substance abuse treatment. Journal of Substance Abuse Treatment, 22, 211-218.
45. Roozen, H. G., de Waart, R., van der Windt, D. A., van den Brink, W., de Jong, C. A., & Kerkhof, A. J. (2006). A systematic review of the effectiveness of naltrexone in the maintenance treatment of opioid and alcohol dependence. European Neuropsychopharmacology, 16, 311-323.
46. Rychtarik, R. G., Connors, G. J., Dermen, K. H., & Stasiewicz, P. R. (2000). Alcoholics Anonymous and the use of medications to prevent relapse: An anonymous survey of member attitudes. Journal of Studies on Alcohol, 61, 134-138.
47. Smith-Rohrberg, D., Bruce, R. D., & Altice, F. L. (2004). Research note- Review of corrections-based therapy for opiate dependent patients: Implications for buprenorphine treatment among correctional populations. Journal of Drug Issues, 34, 451-480.
48. Swift, R. M., Duncan, D., Nirenberg, T. D., & Femino, J. (1998). Alcoholic patients’ experience and attitudes on pharmacotherapy for alcoholism. Journal of Addictive Diseases, 17, 35-48.
49. Swift, R., Oslin, D. W., Alexander, M., & Forman, R. (2011). Adherence monitoring in naltrexone pharmacotherapy trials: A systematic review. Journal of Studies on Alcohol and Drugs, 72, 1012-1018.
50. Syed, Y. Y., & Keating, G. M. (2013). Extended-release intramuscular naltrexone (VIVITROL®): A review of its use in the prevention of relapse to opioid dependence in detoxified patients. CNS Drugs, 27, 851-861.
51. Tabachnick, B. G., & Fidell, L. S. (2007). Using multivariate statistics. Boston, MA: Allyn and Bacon.
52. Taxman, F. S., Perdoni, M. L., & Harrison, L. D. (2007). Drug treatment services for adult offenders: The state of the state. Journal of Substance Abuse Treatment, 32, 239-254.
53. Thomas, S. E., Miller, P. M., Randall, P. K., & Book, S. W. (2008). Improving acceptance of naltrexone in community addiction treatment centers: A pilot study. Journal of Substance Abuse Treatment, 35, 260-268.
54. Thomas, C. P., Wallack, S. S., Lee, S., McCarty, D., & Swift, R. (2003). Research to practice: Adoption of naltrexone in alcoholism treatment. Journal of Substance Abuse Treatment, 24, 1-11.
55. Volpicelli, J. R., Rhines, K. C., Rhines, J. S., Volpicelli, L. A., Alterman, A. I., & O’Brien, C. P. (1997). Naltrexone and alcohol dependence. Role of subject compliance. Archives of General Psychiatry, 54, 737-742.
56. Walters, S. T., Clark, M. D., Gingerich, R., & Meltzer, M. L. (2007). Motivating offenders to change: A guide for probation and parole (NIC Accession number 022253). Washington, DC: National Institute of Corrections.